---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-078152"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:30:54.842343+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OS Therapies Q2 net loss $4.5M; FDA confirms RMAT, issues BLA number for OST-HER2, Phase 2b data positive

## Summary
- FDA confirmed OST-HER2 meets biological criteria for RMAT; issued BLA number for Accelerated Approval submission.
- Phase 2b trial: 12-month EFS 35% vs 20% (p=0.0197), interim 2-year OS 66.6% vs 40% (p=0.0046).
- Q2 2025 net loss $4.537M vs $1.557M YoY; EPS loss $0.19 on 25.1M shares vs $0.26 on 5.99M shares.
- End of Phase 2 FDA meeting scheduled Aug 27, 2025; projected rolling BLA submission late Q3 2025.
- $4.2M capital raise closed July 11; entered ATM offering up to $18M; commercial partner Eversana for possible 1H 2026 launch.

## SEC filing metadata
- accession: 0001213900-25-078152
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390025078152/0001213900-25-078152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390025078152/ea0253711-8k_ostherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-078152
- JSON: https://secwatch.observer/filing/0001213900-25-078152.json
- Plain text: https://secwatch.observer/filing/0001213900-25-078152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.